[Clinical study on improving effect of Buyang Huanwu decoction on plasma thromboxane B2, 6-keto-prostaglandin F1 alpha, endothelin and calcitonin gene related peptide in primary nephrotic syndrome patients]

Plain-language guide to PMID 11475715 (1998): randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide) in 35 patients, alpha-gal syndrome.

Key Facts

PMID: 11475715
Journal: Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
Year: 1998
Study type: Randomized Controlled Trial
Authors: Wu Y et al. (3 authors)

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at CGRP (Calcitonin Gene-Related Peptide) in the context of alpha-gal syndrome.

To explore the mechanism of Buyang Huanwu Decoction (BHD) in treating primary nephrotic syndrome (PNS).

Who Took Part

According to the abstract, 35 patients were involved.

The age groups tagged for this paper are teenagers, adults and middle-aged adults, both men and women.

Based on the treatment of prednisone acetate and cytoxan, two groups of PNS patients were treated with aspirin and persantin (western medicine group, 35 patients) and BHD and western medicine (TCM-WM group, 35 patients) respectively.

Another group of 30 healthy person was established for control.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

The effect on anticoagulation was observed and compared.

The therapeutic effect of the two groups were also observed.

What Was Measured

Topics PubMed links to this paper include 6-Ketoprostaglandin F1 alpha, Calcitonin Gene-Related Peptide, Drugs, Chinese Herbal, Endothelins, Nephrotic Syndrome, Prednisone and Thromboxane B2.

What This Means in Plain Language

The paper is a randomized study of CGRP (Calcitonin Gene-Related Peptide) in 35 patients in people with alpha-gal syndrome.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1998 (Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine), a journal based in China.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Alpha-gal syndrome research.

Our Notes on the Compound

CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.